CD274 and anal carcinoma: A recent study reported 56% of PD-L1 positive anal cancer samples [10], and positive lesions had a less favorable prognosis (increased local recurrence and mortality rates) supporting the hypothesis that anti PD-1/PD-L1 therapy may be effective to treat this invasive neoplasia.